Online Program Home
My Program

Keyword Search

Legend:
CC = Vancouver Convention Centre   F = Fairmont Waterfront Vancouver
* = applied session       ! = JSM meeting theme

Keyword Search Criteria: surrogate endpoint returned 10 record(s)
Monday, 07/30/2018
Inference on Treatment Effect Modification by Marker Response in a Baseline Surrogate Measure Three-Phase Sampling Design
Michal Juraska, Fred Hutchinson Cancer Research Center; Ying Huang, Fred Hutchinson Cancer Research Center; Peter Gilbert, Fred Hutchinson Cancer Research Center
10:50 AM

A Unified Approach to the Statistical Evaluation of Differential Vaccine Efficacy
Erin Gabriel, Karolinska Institute; Dean Follmann, NIAID
11:20 AM

Statistical Approaches for Assessing the Utility of Urinary Glycosaminoglycans as a Surrogate Endpoint in Clinical Trials
Di Xiao, The Food and Drug Adminstration; Yeh-Fong Chen, US FDA; Min Min, U.S. Food and Drug Administration, CDER/OTS/OB
3:05 PM

Tuesday, 07/31/2018
Relationship Between ORR, PFS and OS in Patients Treated with Anti-PD1/PDL1 Therapies
Jiabu Ye, AstraZeneca; Pralay Mukhopadhyay, Astrazeneca; Xiang Ji, AstraZeneca


Statistical Approaches for Assessing the Utility of Urinary Glycosaminoglycans as a Surrogate Endpoint in Clinical Trials
Di Xiao, The Food and Drug Adminstration; Yeh-Fong Chen, US FDA; Min Min, U.S. Food and Drug Administration, CDER/OTS/OB


Relationship Between ORR, PFS and OS in Patients Treated with Anti-PD1/PDL1 Therapies
Jiabu Ye, AstraZeneca; Pralay Mukhopadhyay, Astrazeneca; Xiang Ji, AstraZeneca
9:45 AM

On the Relationship Between the Causal-Inference and Meta-Analytic Paradigms for the Evaluation of Surrogate Endpoints
Geert Molenberghs, Universiteit Hasselt & Katholieke Universiteit Leuven
10:35 AM

Assessment of Biomarkers and Surrogate Endpoints in Drug Development
Ivan Chan, AbbVie Inc; Shu-Chih Su, Merck Research Labs
10:55 AM

Identifying and Validating Surrogate Endpoints for Overall Survial (OS) in Metastatic Castration-Resistant Prostate Cancer
Xiaowei Guan, Pfizer, Inc.; Michelle Casey, Pfizer, Inc.; De Phung, Astellas Pharma, Inc. ; Suha Sari, Pfizer, Inc.; Eren Demirhan, Pfizer, Inc.
11:35 AM

Wednesday, 08/01/2018
A Model-Based Approach for Simulating Adaptive Clinical Studies with Surrogate Endpoints Used for Interim Decision-Making
Xiaotian Chen, AbbVie; Alan Hartford, AbbVie Inc; Mei Li, AbbVie; Jun Zhao, AbbVie
9:20 AM